Last reviewed · How we verify

HES 130/0.4 (Voluven) — Competitive Intelligence Brief

HES 130/0.4 (Voluven) (HES 130/0.4 (Voluven)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic colloid volume expander. Area: Critical Care / Anesthesia.

phase 3 Synthetic colloid volume expander Critical Care / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

HES 130/0.4 (Voluven) (HES 130/0.4 (Voluven)) — The Cleveland Clinic. HES 130/0.4 is a synthetic colloid that expands intravascular volume by drawing fluid into the bloodstream to maintain hemodynamic stability.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HES 130/0.4 (Voluven) TARGET HES 130/0.4 (Voluven) The Cleveland Clinic phase 3 Synthetic colloid volume expander
Hydroxyethylstarch 130/0,4 Hydroxyethylstarch 130/0,4 Rigshospitalet, Denmark marketed Synthetic colloid volume expander

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic colloid volume expander class)

  1. Rigshospitalet, Denmark · 1 drug in this class
  2. The Cleveland Clinic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HES 130/0.4 (Voluven) — Competitive Intelligence Brief. https://druglandscape.com/ci/hes-130-0-4-voluven. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: